4/26/2013

Phase II trial data showed AcelRx Pharmaceuticals' experimental pain drug ARX-04 met the main study goal of reducing acute pain at a dosage of 30 micrograms but not at 20 mcg. The study compared both dosages against a placebo.

Full Story:
Reuters

Related Summaries